Rome

• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• A clinical trial to be conducted in many hospitals and in different countries with the medicinal substance Regadenoson to be used in a type … Recruiting
  2024-515244-22-00 9 2024-09-09 Patients who need to undergo a clinically indicated pharmacologic stre
• Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS Recruiting
  2023-505051-43-00 5 2024-09-04 juvenile idiopathic arthritis
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-506704-14-00 4 2024-09-04 Moderately to Severely Active Crohn's Disease
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasis Recruiting
  2023-503859-10-00 5 2024-08-12 Moderate to Severe Plaque Psoriasis
• Phase 1/2a study of ATX-01 in participants with DM1 Recruiting
  2023-505363-37-00 1 2024-08-12 Myotonic dystrophy type 1 (DM1)
• Preventing caRdiovascular collapsE with VasoprEssors duriNg Tracheal IntubatiON: The PREVENTION Randomized Controlled Trial (PREVENTION tria … Recruiting
  2023-503895-25-00 5 2024-08-01 criticall illness
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting
  2023-508703-21-00 9 2024-08-01 Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), bili
• COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients t … Recruiting
  2024-515883-30-00 6 2024-08-01 St-Elevated Myocardial Infartion
• A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Recruiting
  2023-506503-26-00 5 2024-07-31 Polyneuropathy, Inflammatory Demyelinating, Chronic
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 6 2024-07-31 Moderately to Severely Active Crohn’s Disease
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and … Recruiting
  2023-508482-32-00 5 2024-07-22 Neutropenias
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate … Recruiting
  2024-511309-47-00 4 2024-07-17 moderate thrombocytopenia
• A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting
  2023-504910-31-00 5 2024-07-15 Non-small Cell Lung Cancer (NSCLC)
• Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s … Recruiting
  2024-515049-41-00 4 2024-07-12 metastatic prostate cancer
• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)

Showing 841–864 of 2,096 trials